Compositions comprising hiv-1 envelopes with engineered v1v2 or mrnas encoding the same for broad v3-glycan neutralizing antibody binding
OwnerKevin O. SAUNDERS, Barton F. HAYNES +2inventors
InventorsKevin O. SAUNDERS, Barton F. HAYNES, Daniel WRAPP, Drew WEISSMAN
Life of this patent
Estimating the term…
Abstract
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
Claims58
A recombinant HIV-1 envelope comprising all the consecutive amino acids after the signal peptide of SEQ ID NOs:
- 19-30, 33, 35-45, 52-63 or 288-303.
A method of inducing an immune response in a subject comprising administering an immunogenic composition comprising any one of the recombinant HIV-1 envelopes the preceding claims or compositions of the preceding claims, in an amount sufficient to induce an immune response.
A nucleic acid sequence comprising SEQ ID NOs 64-94 or 304-330.
A method of inducing an immune response comprising administering an immunogenic composition comprising a prime immunogen comprising all the consecutive amino acids after the signal peptide of SEQ ID NOs:
- 19-30, 33, 35-45, 52-63 or 288-303 or a nucleic acid sequence encoding all the consecutive amino acids after the signal peptide of SEQ ID NOs:
- 19-30, 33, 35-45, 52-63 or 288-303 followed by at least one boost immunogen from Table 3 or Table 4, wherein the boost immunogens are administered in the order appearing in Table 4, in an amount sufficient to induce an immune response.
An immunogenic composition or composition of any of the preceding claims, wherein the composition comprises at least two different recombinant HIV-1 envelopes or nucleic acids encoding a HIV-1 envelope, or a combination thereof.
An immunogenic composition comprising a first immunogen and a second immunogen, wherein the first immunogen is a HIV-1 envelope comprising all the consecutive amino acids after the signal peptide of SEQ ID NOs:
- 19-30, 33, 35-45, 52-63 or 288-303, or a nucleic acid sequence comprising SEQ ID NOs:
- 64-94 or 304-330, and wherein the second immunogen is a different HIV-1 envelope comprising all the consecutive amino acids after the signal peptide of SEQ ID NOs:
- 19-30, 33, 35-45, 52-63 or 288-303, or a nucleic acid sequence comprising SEQ ID NOs:
- 64-94 or 304-330.
A recombinant trimer comprising three identical protomers of an envelope comprising all the consecutive amino acids after the signal peptide of SEQ ID NOs:
- 19-30, 33, 35-45, 52-63 or 288-303.
Dependencies are inferred from the claim text.